Natalie Finn, Author at BioTuesdays

Developments

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Tonix Pharmaceuticals (NASDAQ:TNXP) agreed to acquire two currently-marketed products from Upsher-Smith Laboratories: Zembrace SymTouch injection 3 mg, and Tosymra nasal spray 10 mg, for the treatment of acute migraine...

June 26, 2023

Developments

Talaris Therapeutics to merge with Tourmaline Bio

Talaris Therapeutics (NASDAQ:TALS) and closely-held Tourmaline Bio agreed to merge in an all-stock transaction. The combined company will focus on advancing Tourmaline’s lead program, TOUR006, a potentially best-in...

June 22, 2023

Markets

Quipt Home Medical up-lists to TSX

Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) received final approval to list its common shares on the Toronto Stock Exchange and will commence trading on the TSX at the market open on June 21 under the symbol, QIPT. With...

June 20, 2023

Developments

Rhythm presents BMI reduction data in hypothalamic obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) presented data that showed meaningful weight loss was sustained and progressed in patients with hypothalamic obesity treated with its setmelanotide for six months as part of the long...

June 19, 2023

Developments

Hepion to present 2 posters at EASL International Liver Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) will present two abstracts for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 taking place June 21 – 24 in...

June 16, 2023

Developments

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

A data and safety monitoring board (DSMB) has reviewed the current data for Hepion Pharmaceuticals’ (NASDAQ:HEPA) ASCEND-NASH Phase 2b trial with rencofilstat and issued a “study may proceed without modification”...

June 15, 2023

Developments

Confo, AbCellera in GPCR-targeting antibody discovery program

Confo Therapeutics of Belgium entered into a research collaboration with AbCellera Biologics (NASDAQ:ABCL) for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets (G protein-coupled...

June 15, 2023

Developments

Blue Water acquires 6 FDA-approve drugs across various indication

Blue Water Biotech (NASDAQ:BWV) signed asset purchase agreements with WraSer and Xspire Pharma to acquire six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management...

June 14, 2023

Markets

AGP starts UpHealth at buy; PT $4.30

Alliance Global Partners initiated coverage of UpHealth (NYSE:UPH) with a “buy” rating and price target of $4.30. The stock closed at $1.45 on June 8. UpHealth operates as a digital health services company in the...

June 9, 2023

Developments

Annovis Bio completes enrollment in Phase 3 Parkinson’s trial

Annovis Bio’s (NYSE:ANVS) Parkinson’s disease (PD) Phase 3 clinical trial of its lead compound, buntanetap, reached full enrollment in a record nine months after it began. Since the first patient was dosed in late...

June 8, 2023

Author - Natalie Finn

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Talaris Therapeutics to merge with Tourmaline Bio

Quipt Home Medical up-lists to TSX

Rhythm presents BMI reduction data in hypothalamic obesity

Hepion to present 2 posters at EASL International Liver Congress

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

Confo, AbCellera in GPCR-targeting antibody discovery program

Blue Water acquires 6 FDA-approve drugs across various indication

AGP starts UpHealth at buy; PT $4.30

Annovis Bio completes enrollment in Phase 3 Parkinson’s trial

General

More